{"title":"为欧洲应对未来的健康威胁和危机做好准备─ 欧洲药品管理局;确保安全有效的药品和医疗器械。","authors":"Emer Cooke","doi":"10.2807/1560-7917.ES.2022.27.42.2200798","DOIUrl":null,"url":null,"abstract":"Despite the absence of an explicit legal mandate and appropriate resources, EMA quickly introduced a structure to coordinate activities and established processes which were crucial for an effective EU-wide response. For example, EMA coordinated the exchange of information and actions to identify and mitigate medicine shortages between EU countries when global pharmaceutical supply chains were disrupted almost overnight because of border closures and lockdowns and there was an increased demand for medicines, particularly in the intensive care unit setting. However, it became clear early in the pandemic that EMA needed stronger legal tools to help ensure the availability of medicinal products and medical devices and to support the development of new therapeutics to protect the health of Europeans in times of crisis.","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585881/pdf/","citationCount":"4","resultStr":"{\"title\":\"Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices.\",\"authors\":\"Emer Cooke\",\"doi\":\"10.2807/1560-7917.ES.2022.27.42.2200798\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite the absence of an explicit legal mandate and appropriate resources, EMA quickly introduced a structure to coordinate activities and established processes which were crucial for an effective EU-wide response. For example, EMA coordinated the exchange of information and actions to identify and mitigate medicine shortages between EU countries when global pharmaceutical supply chains were disrupted almost overnight because of border closures and lockdowns and there was an increased demand for medicines, particularly in the intensive care unit setting. However, it became clear early in the pandemic that EMA needed stronger legal tools to help ensure the availability of medicinal products and medical devices and to support the development of new therapeutics to protect the health of Europeans in times of crisis.\",\"PeriodicalId\":520613,\"journal\":{\"name\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585881/pdf/\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2022.27.42.2200798\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2022.27.42.2200798","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices.
Despite the absence of an explicit legal mandate and appropriate resources, EMA quickly introduced a structure to coordinate activities and established processes which were crucial for an effective EU-wide response. For example, EMA coordinated the exchange of information and actions to identify and mitigate medicine shortages between EU countries when global pharmaceutical supply chains were disrupted almost overnight because of border closures and lockdowns and there was an increased demand for medicines, particularly in the intensive care unit setting. However, it became clear early in the pandemic that EMA needed stronger legal tools to help ensure the availability of medicinal products and medical devices and to support the development of new therapeutics to protect the health of Europeans in times of crisis.